Delayed Release ADHD Dosage Form with Layered Coating

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for ADHD and other CNS stimulant-responsive conditions face challenges in maintaining effective drug concentration throughout the day, particularly in morning and afternoon when cognitive abilities are needed, due to rapid release formulations that lead to compliance issues and side effects.

Innovation Solution

Development of novel pharmaceutical compositions with a core comprising a CNS stimulant, a sustained release layer, and a delayed release layer, allowing for a controlled release of the drug over 4 to 12 hours, providing a therapeutic effect from waking to the active part of the day with a single evening dose.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If immediate release formulations are used for ADHD treatment, then the drug releases quickly to provide rapid therapeutic effect, but compliance becomes problematic due to requiring twice daily administration

Engineering Contradiction:
Improvedrug release speedVSAvoidpatient compliance
Core Design Contradiction:
SpeedVSEase of operation

Solution Approach 1:

The patent segments the drug delivery system into multiple functional layers: an immediate release layer for rapid initial therapeutic effect, a sustained release layer for extended drug delivery, and a delayed release outer layer for controlling the overall release timeline. This segmentation allows the single dose to provide comprehensive coverage throughout the day, eliminating the need for twice-daily administration and improving patient compliance.

Inventive Principle:
Principle #1Segmentation

2Ease of operation

If long-acting formulations are used to extend drug coverage, then compliance improves with once-daily dosing, but the drug cannot provide effective concentration in morning hours when cognitive abilities are needed

Engineering Contradiction:
Improvepatient complianceVSAvoidtherapeutic effect timing
Core Design Contradiction:
Ease of operationVSDuration of action of moving object

Solution Approach 1:

The patent applies preliminary action by incorporating an immediate release layer that releases the drug rapidly upon administration, providing therapeutic effect in the morning hours when cognitive functions are needed. This preliminary release ensures effective concentration is achieved early in the day, while the subsequent sustained and delayed release layers extend coverage throughout the day and into the evening, all from a single morning dose.

Inventive Principle:
Principle #10Preliminary action

3Duration of action of moving object

If sustained release layers are used to extend drug release, then drug coverage is prolonged, but the release rate may not increase sufficiently during active parts of the day

Engineering Contradiction:
Improvedrug release durationVSAvoidtherapeutic effect intensity
Core Design Contradiction:
Duration of action of moving objectVSProductivity

Solution Approach 1:

The patent implements dynamics by designing the sustained release layer with varying release characteristics and the delayed release outer layer that controls the release timeline. This dynamic structure allows the drug release rate to be modulated throughout the day, providing extended duration coverage while ensuring sufficient release intensity during active periods when therapeutic effect is most needed, rather than maintaining a constant low-level release.

Inventive Principle:
Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions ensure a sustained therapeutic effect throughout the day with reduced side effects by delaying and controlling the release of CNS stimulants, improving compliance and minimizing peak drug concentrations, thus enhancing treatment efficacy and patient convenience.

Implementation Method 1

The delayed release layer can thus be a pH dependent layer that is insoluble in aqueous solution at a pH below 5.5 and soluble at the higher pH normally found in the ileum or colon

Methodology Applied
Scientific EffectpH-dependent dissolution:

Implementation Method 2

a sustained release coating at a rate controlled by the sustained release coating

Methodology Applied
Scientific EffectPermeation: Permeation

Data Source

PatentUS9034902B2Methods for treatment of attention deficit hyperactivity disorder
Publication Date: 2015.05.19 IRONSHORE PHARMA & DEV
  • US9034902B2 patent drawing
  • US9034902B2 patent drawing
  • US9034902B2 patent drawing

AI summary

Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.